Introduction
Increasing the value and impact of clinical research
New models for the value-based pricing of pharmaceuticals are actively in development. Decision-makers in healthcare are increasingly using the highest quality scientific evidence to support clinical and health policy choices. It is imperative, more so than ever before, that everyone engaged in the design, conduct and analysis of clinical research focuses on the incorporation of measures that enhance its value and impact.
This conference brings together experts from across the UK’s clinical research community to explore the mechanisms by which this may be achieved.
The agenda and speakers will be announced shortly. Keep updated on the progress by following Events4Health on twitter.
The Annual Conference Agenda
| 09.00 - 09.30 | Registration and coffee |
| 09.30 - 09.35 | Welcome Remarks Sir Gordon Duff, Chairman of the UK’s Commission on Human Medicine (CHM) |
| 09.35 - 10.00 | Key Note Speech The value and impact of clinical research to healthcare (past achievements, future potential) Professor Sir John Tooke, President of the Academy of Medical Sciences |
| 10.00 - 11.20 | Session 1: Commercial R&D Partnerships The industry/NHS clinical research “health-check” Dr Louise Wood, Deputy Director/Head of NHS Research Infrastructure and Growth, Research and Development Directorate at the Department of Health Dr Mark Samuels, Managing Director, NIHR Office for Clinical Research Infrastructure (NOCRI) Dr Tim Cave, Novartis Dr Jeremy Haigh, Amgen Dr Anders Dyhr Toft, Medical Director, Novo Nordisk Dr Neil Bell, Teva Working with Industry; The view from the Medical Research Council Professor Sir John Savill, University of Edinburgh |
| 11.20 - 11.45 | Coffee & Networking in Exhibition Area |
| 11.45 - 13.15 | Session 2: Enhancing patient involvement in clinical trials The patient's view Simon Denegri, Chair, INVOLVE Best practices from top trusts Heidi Neild and Simon Bourne, University Hospital Southampton Dr Martina Prude, University of Southampton Professor Steve Smye, R & D Director for the Leeds Teaching Hospital NHS Trust Dr Clare Morgan, Performance and Industry Director, NIHR CRN Professor John Goodacre, CLRN Clinical Director Helen Quinn, PenCLRN Senior Manager. The oncology experience Eric Low, Myeloma UK Dr Sheila Fisher, NCRN |
| 13.15 - 14.00 | Lunch & Networking in Exhibition Area |
| 14.00 - 15.20 | Session 3: The assessment of value in clinical research Value-based pricing; What is it and where is it at? Leslie Galloway, Chairman, EMIG How does society weight health benefits? Professor Karl Claxton, Professor of Economics, University of York What do rare diseases tell us about value assessment? Josie Godfrey, Advisory Group for National Specialised Services What new value measures are needed in clinical research to assist decision-makers? Professor Ken Paterson |
| 15.20 - 15.45 | Coffee & Networking in Exhibition Area |
| 15.45 - 16.45 | Session 4: Ensuring enabling regulation Progressing the work of the Health Research Authority Dr Janet Wisely, Interim Chief Executive HRA How regulation can keep pace with innovation Professor Sir Kent Woods, Chief Executive, MHRA |
| 16.45 - 17.00 | Summary Comments and Wrap Up Sir Gordon Duff, Chairman of the UK’s Commission on Human Medicine (CHM) |
Media Partners
